Astellas Pharma Inc: Phase 4 study closed enrollment, 17 enrolled (Geographic Atrophy, Age-Related Macular Degeneration)
Astellas Pharma Inc: Phase 4 study closed enrollment, 17 enrolled (Geographic Atrophy, Age-Related Macular Degeneration). Its enrollment of 17 is below the median of 80 (7th percentile). Dated 6 days ago, it is inside the fresh trigger window. Score 75/100. As of 2026-11-04, from ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
Data as of · Compiled by Zalwin from ClinicalTrials.gov (U.S. National Library of Medicine) API v2
enrollment: 17 · 7th percentile of 8,879 ClinicalTrialStartPulse records · 0.2x the median
Free preview: all 15 published fields of this record are shown below. Locked: 499 related ClinicalTrialStartPulse records and the 7-column CSV export.
| Field | Value |
|---|---|
| Sponsor | Astellas Pharma Inc |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration |
| NCT ID | NCT06970665 |
| Phase | Phase 4 |
| Status | active not recruiting |
| Conditions | Geographic Atrophy; Age-Related Macular Degeneration |
| Intervention types | drug |
| Target enrollment | 17 |
| Site countries | Japan |
| Posted | 2025-05-14 |
| Planned start | 2025-07-08 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-30 |
| Last update posted | 2026-10-30 |
| enrollment percentile | 7th of 8,879 (median 80, 0.2x median) |
| Peer records CSV (500 records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch Astellas Pharma Inc
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Free first: a 10-record sample of records
See the real columns before you buy. One confirmation email, nothing else unless you opt in.
Unlock Astellas Pharma + 500 peer records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Sponsor · Phase · Conditions · Enrollment · Countries · Event · Posted · official source URL
- Source agency: ClinicalTrials.gov (U.S. National Library of Medicine) API v2
- Record date: 2026-10-30
- Data refreshed: 2026-11-04
- Refunds on request within 14 days
Top ClinicalTrialStartPulse records (NONUS first): University of Oxford · DejthidaNathaphong · Eye & ENT Hospital of Fudan University · Shanghai First Maternal and Infant Health Hospital affiliate · Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Browse all by state and category →
LIVE PUBLIC DATA Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 · Last refreshed: Wed, 04 Nov 2026 06:04:38 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: Astellas Pharma Inc and 6,603 NONUS peers
- NONUS ClinicalTrialStartPulse records like this one: 6,603
- Astellas Pharma Inc's enrollment: 7th percentile of 8,879 records
- Timing: High: dated in the last 7 days
- Estimated pipeline if you contact every NONUS peer: $1,320,600 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
75 / 100 Score
- Posted in the last two weeks.
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
What is the ClinicalTrialStartPulse record for Astellas Pharma Inc?
Astellas Pharma Inc's Phase 4 study (NCT06970665) in Geographic Atrophy, first posted 2025-05-14: enrollment closed (active, not recruiting) (2026-10-30), in an update posted 2026-10-30.
How does Astellas Pharma Inc compare to other ClinicalTrialStartPulse records?
Its enrollment of 17 is below the median (7th percentile); smaller records often move faster and face less competition. It is fresh: dated 6 days ago, inside the window where early outreach matters most. Its Score of 75/100 puts it among the stronger signals in this feed.
Astellas Pharma Inc vs. top 3 peers
| Organization | Location | Amount | Percentile | Record date |
|---|---|---|---|---|
| Astellas Pharma Inc | NONUS | 17 | 7th | 2026-10-30 |
| Merck Sharp & Dohme LLC | NONUS | 30 | 19th | 2026-10-22 |
| Sanofi | NONUS | 56 | 37th | 2026-10-29 |
| Johnson & Johnson Private Limited | NONUS | 75 | 48th | 2026-11-03 |
Related records
ClinicalTrialStartPulse: Phase 4 ClinicalTrialStartPulse: Outside the US only
How to monitor Astellas Pharma Inc and peer phase 4 records
Get new ClinicalTrialStartPulse records like Astellas Pharma Inc by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new studies in your therapeutic areas
ClinicalTrialStartPulse emails new studies and status changes matching your events, phases, sponsor types and site regions.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.